MyoKardia's $75M IPO pitch could be the next big test of biotech's meddle

MyoKardia, expected to go public this week, is poised to become the next barometer of biotech's status on Wall Street, angling for a $75 million debut as investors take a tepid approach to drug developers. The company, founded by Third Rock Ventures, is at work on treatments for rare cardiac disorders, planning to spend its IPO haul on accelerating its top prospects into clinical development. MyoKardia's planned offering comes amid weeks of sluggish returns for biotechs going public, as the once-bullish market has gradually soured, forcing most recent debutantes to accept cheaper shares and smaller valuations.

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.